Semanteon Capital Management LP Purchases 43,288 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Semanteon Capital Management LP increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 40.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,156 shares of the biopharmaceutical company's stock after buying an additional 43,288 shares during the period. Semanteon Capital Management LP's holdings in Amicus Therapeutics were worth $1,405,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of FOLD. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Amicus Therapeutics in the 3rd quarter worth approximately $55,000. R Squared Ltd bought a new position in Amicus Therapeutics in the fourth quarter worth $79,000. KBC Group NV lifted its position in Amicus Therapeutics by 44.4% during the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 3,120 shares during the period. Stephens Inc. AR purchased a new stake in shares of Amicus Therapeutics in the 4th quarter worth about $101,000. Finally, AlphaQuest LLC increased its stake in shares of Amicus Therapeutics by 635.1% in the 4th quarter. AlphaQuest LLC now owns 10,732 shares of the biopharmaceutical company's stock worth $101,000 after acquiring an additional 9,272 shares in the last quarter.

Amicus Therapeutics Stock Performance

NASDAQ FOLD traded down $0.07 during trading hours on Tuesday, hitting $8.62. 3,054,322 shares of the company's stock traded hands, compared to its average volume of 2,405,960. Amicus Therapeutics, Inc. has a 52 week low of $8.55 and a 52 week high of $12.65. The firm has a market capitalization of $2.65 billion, a P/E ratio of -47.89, a P/E/G ratio of 1.51 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. The business's fifty day moving average price is $9.34 and its two-hundred day moving average price is $10.04.

Remove Ads

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on FOLD shares. Cantor Fitzgerald restated an "overweight" rating and issued a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Morgan Stanley restated an "equal weight" rating and issued a $12.00 price target (down previously from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Wells Fargo & Company lowered their price objective on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Needham & Company LLC reissued a "hold" rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. Finally, StockNews.com downgraded Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, February 20th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, Amicus Therapeutics has an average rating of "Moderate Buy" and an average target price of $16.75.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.